150 related articles for article (PubMed ID: 9626204)
21. Waldenström's macroglobulinemia: clinical features, complications, and management.
Dimopoulos MA; Panayiotidis P; Moulopoulos LA; Sfikakis P; Dalakas M
J Clin Oncol; 2000 Jan; 18(1):214-26. PubMed ID: 10623712
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Peinert S; Tam CS; Prince HM; Scarlett J; Wolf MM; Januszewicz EH; Westerman D; Seymour JF
Leuk Lymphoma; 2010 Dec; 51(12):2188-97. PubMed ID: 20939696
[TBL] [Abstract][Full Text] [Related]
23. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.
Facon T; Brouillard M; Duhamel A; Morel P; Simon M; Jouet JP; Bauters F; Fenaux P
J Clin Oncol; 1993 Aug; 11(8):1553-8. PubMed ID: 8336194
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
26. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
27. Second treatment with fludarabine in a Waldenström's macroglobulinemia patient.
Maloisel F; Campos F; Giron C; Dufour P
Leukemia; 2000 Jan; 14(1):220. PubMed ID: 10637502
[No Abstract] [Full Text] [Related]
28. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
29. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
Dimopoulos MA; Weber DM; Kantarjian H; Keating M; Alexanian R
Ann Oncol; 1994 Mar; 5(3):288-9. PubMed ID: 7514439
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
31. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
32. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Lévy V; Porcher R; Leblond V; Fermand JP; Cazin B; Maloisel F; Harousseau JL; Remenieras L; Guibon O; Chevret S;
Leukemia; 2001 Sep; 15(9):1466-70. PubMed ID: 11516109
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
34. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
[TBL] [Abstract][Full Text] [Related]
35. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Johnson SA
Hematol J; 2004; 5 Suppl 1():S50-61. PubMed ID: 15079153
[TBL] [Abstract][Full Text] [Related]
36. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
[TBL] [Abstract][Full Text] [Related]
37. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
38. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
39. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Dimopoulos MA; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
J Clin Oncol; 1994 Dec; 12(12):2694-8. PubMed ID: 7989946
[TBL] [Abstract][Full Text] [Related]
40. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]